NeoPharm 
Welcome,         Profile    Billing    Logout  
 5 Products   63 Diseases   5 Products   156 Trials   7159 News 


«12...7891011121314151617...8081»
  • ||||||||||  Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
    Effectiveness of anti-B-cell maturation antigen (BCMA)-targeting therapy after selinexor treatment. () -  Apr 26, 2023 - Abstract #ASCO2023ASCO_6241;    
    P1b/2, P2b
    In this cohort of heavily-pretreated pts with MM who received a selinexor regimen prior to NCA, overall survival was in the range of 1 year, akin to historical results seen with ADCs. The 8-week median time between administration of selinexor and NCAs suggests that selinexor, with various partner agents, did not negatively impact overall survival with subsequent NCA therapy.
  • ||||||||||  Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
    Metronomic dosing of selinexor in select soft tissue sarcomas (STS). (On Demand | Hall A; Poster Bd # 491) -  Apr 26, 2023 - Abstract #ASCO2023ASCO_2820;    
    P1
    Signs of potential clinical benefit was seen in the form of SD. Further data comparison with historical controls and PK analysis are needed to put this finding into perspective.
  • ||||||||||  elranatamab (PF-06863135) / Pfizer
    An indirect comparison of elranatamab (On Demand | Hall A; Poster Bd # 110) -  Apr 26, 2023 - Abstract #ASCO2023ASCO_2717;    
    P=N/A
    Among TCR MM patients who resemble those of the MM-3 trial, ELRA showed improved ORR compared with treatments currently used in clinical practice. >FH, Flatiron Health; CI, confidence interval; ORR, objective response rate; RR, rate ratio.*Some patients were excluded from the IPTW and doubly robust analyses due to missing values for variables used in the propensity score model.
  • ||||||||||  Jakafi (ruxolitinib) / Novartis, Incyte, Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
    Selinexor (SEL) plus ruxolitinib (RUX) in JAK inhibitor (JAKi) treatment-na (On Demand | Hall A; Poster Bd # 193) -  Apr 26, 2023 - Abstract #ASCO2023ASCO_838;    
    P1/2
    Updated data will be available for presentation. Clinical trial information: NCT04562389.
  • ||||||||||  Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
    Selinexor: the latest clinical data () -  Apr 20, 2023 - Abstract #COMy2023COMy_120;    
    Not yet recruiting --> Recruiting | Trial completion date: May 2028 --> Mar 2033 | Trial primary completion date: Jul 2027 --> Mar 2028 Supported by Menarini-Stemline
  • ||||||||||  eltanexor (KPT-8602) / Ono Pharma, Karyopharm, Antengene, Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
    Journal, IO biomarker, Synthetic lethality:  Synthetic lethal targeting of TET2-mutant haematopoietic stem and progenitor cells by XPO1 inhibitors. (Pubmed Central) -  Apr 20, 2023   
    Selective killing of TET2-mutant HSPCs and human AML cells by these inhibitors was due to increased levels of apoptosis, without evidence of DNA damage based on increased ?H2AX expression. The finding that TET2 loss renders HSPCs and AML cells selectively susceptible to cell death induced by XPO1 inhibitors provides preclinical evidence of the selective activity of these drugs, justifying further clinical studies of these small molecules for the treatment of TET2-mutant haematopoietic malignancies, and to suppress clonal expansion in age-related TET2-mutant clonal haematopoiesis.
  • ||||||||||  Simulect (basiliximab) / Novartis, Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Grafalon (rabbit anti-T-lymphocyte globulin) / Mundipharma, NeoPharm
    CHRONIC CMV DIARRHOEA IN RENAL TRANPLANT RECIPIENTS - AN UNDERRECOGNISED SPECTRUM OF COMPARTMENTALISED GUT INVASIVE CMV DISEASE. (Amber 6) -  Apr 15, 2023 - Abstract #ERAEDTA2023ERA_EDTA_625;    
    Only 31.9% and 26.8% received Valganciclovir prophylaxis for pre-specified indications respectively... Compartmentalized gut invasive CMV represents a larger proportion of chronic diarrhoeal illness with a higher relapse rate, which needs invasive gut tissue PCR analysis, despite negative blood PCR, for early diagnosis and management.
  • ||||||||||  Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
    Review, Journal:  The efficacy of selinexor (KPT-330), an XPO1 inhibitor, on non-hematologic cancers: a comprehensive review. (Pubmed Central) -  Apr 14, 2023   
    Compartmentalized gut invasive CMV represents a larger proportion of chronic diarrhoeal illness with a higher relapse rate, which needs invasive gut tissue PCR analysis, despite negative blood PCR, for early diagnosis and management. Further clinical investigation of selinexor treatment for solid malignancies is warranted.
  • ||||||||||  Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
    Selinexor (Twitter) -  Apr 11, 2023   
  • ||||||||||  Relyvrio (phenylbutyrate/taurursodiol) / Amylyx
    Trial completion, Enrollment change:  A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) -  Apr 7, 2023   
    P2/3,  N=28, Completed, 
    This new experimental model and analysis provide a more precise screening method for developing improved therapeutics targeting AML cells within the cytoprotective BM microenvironment. Active, not recruiting --> Completed | N=40 --> 28
  • ||||||||||  Paxlovid (nirmatrelvir and ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
    ORAL ANTIVIRALS RITONAVIR-NIRMATRELVIR AND MOLNUPIRAVIR ARE HIGHLY EFFECTIVE IN PATIENTS WITH MULTIPLE MYELOMA AND COVID-19; A SINGLE-CENTER, PROSPECTIVE STUDY (Poster Area) -  Apr 4, 2023 - Abstract #EMN2023EMN_200;    
    These included proteasome inhibitors based regimen, immunomodulatory drugs based regimen, anti-CD38 monoclonal antibody based regimen, anti-BCMA based regimen, and other treatments, such as selinexor and cyclophosphamide...The special treatment included hospitalization in 6.7% of patients with moderate infection (1 patient) and 100% of patients with severe infection (5 patients), tocilizumab in 5 patients with severe infection, intubation in 2 patients severely infected (40% of patients with severe infection) and corticosteroids in 13 patients with moderate infection (86.7% of these patients) and 5 with a severe one (100% of these patients)...Regarding treatment, despite the various drug types included in the study and their combinations, it was observed that treatment with belantamab mafodotin was significantly related to the outcome...Ritonavir-nirmatrelvir and molnupiravir seem to be highly effective in preventing severe disease and mortality from SARS-CoV-2 infection in MM patients who are under treatment for the underlying disease. This prospective study indicates the comparable effects of the two treatment options providing an important background for further research.
  • ||||||||||  Treatment of triple-class refractory disease: beyond immunotherapy (Grote Zaal) -  Apr 4, 2023 - Abstract #EMN2023EMN_63;    
    In addition, venetoclax has demonstrated significant activity in t(11;14) MM patients and represents another therapeutic option. The most appropriate sequencing of existing therapies and the most potent treatment combination still remains unanswered.
  • ||||||||||  Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
    Review, Journal:  Selinexor-Bortezomib-Dexamethasone: A Review in Previously Treated Multiple Myeloma. (Pubmed Central) -  Mar 29, 2023   
    The triplet regimen uses less bortezomib and dexamethasone during the first 24 weeks of treatment. The efficacy and safety profiles of selinexor-bortezomib-dexamethasone, combined with its once-weekly administration of selinexor and bortezomib, make it a useful additional triplet therapy option for previously treated multiple myeloma.
  • ||||||||||  Xpovio (selinexor) / Karyopharm
    Enrollment closed, Trial completion date, Trial primary completion date:  SEARCH: A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) -  Mar 29, 2023   
    P2,  N=60, Active, not recruiting, 
    The efficacy and safety profiles of selinexor-bortezomib-dexamethasone, combined with its once-weekly administration of selinexor and bortezomib, make it a useful additional triplet therapy option for previously treated multiple myeloma. Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Jun 2024 | Trial primary completion date: Mar 2023 --> Dec 2023
  • ||||||||||  Simulect (basiliximab) / Novartis, Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Grafalon (rabbit anti-T-lymphocyte globulin) / Mundipharma, NeoPharm
    A SINGLE CENTRE TWO-DECADE EXPERIENCE ON CYTOMEGALOVIRUS (CMV) DISEASE IN POST-RENAL TRANSPLANT RECIPIENTS  () -  Mar 28, 2023 - Abstract #ISNWCN2023ISN_WCN_1532;    
    Only 14.8%, 31.9% and 26.8% received Valgancyclovir prophylaxis for pre-specified indications in three groups...Higher mortality rate was seen in acute CMV (44%) and mean time to death from infection was 208 months. Conclusions Compartmentalized CMV colitis represents a larger proportion of chronic diarrhoeal illness, which needs invasive quantitative tissue PCR analysis, despite having negative blood PCR, for early diagnosis and management.
  • ||||||||||  Promacta (eltrombopag) / Novartis, Grafalon (rabbit anti-T-lymphocyte globulin) / Mundipharma, NeoPharm
    A novel use of tacrolimus to treat aplastic anemia in a renal transplant recipient () -  Mar 28, 2023 - Abstract #ISNWCN2023ISN_WCN_1499;    
    He was started on Eltrombopag and cyclosporine in January 2021...He underwent renal-transplantation in April 2021 with anti-lymphocyte-globulin (Grafalon- 200mg) as induction...Reasons being- due to his aplastic anemia, his mycophenolate mofetil dosage was kept below optimal levels to prevent a drop in his total WBC count; therefore, it was crucial to maintain his CNI inhibitor and steroids at their optimum levels and tacrolimus is a better immunosuppressant...Currently, he is 1.5 years post renal transplantation and his platelet count is 1.3 lac/mm 3 and his hemoglobin is 13.1g/dl. Conclusions In this case, tacrolimus was used for treatment of moderate aplastic anemia and also as a part of immunosuppression post renal transplantation.
  • ||||||||||  Xpovio (selinexor) / Karyopharm
    Enrollment closed, Metastases:  SELISARC: Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma and Osteosarcoma (clinicaltrials.gov) -  Mar 27, 2023   
    P1/2,  N=14, Active, not recruiting, 
    Conclusions In this case, tacrolimus was used for treatment of moderate aplastic anemia and also as a part of immunosuppression post renal transplantation. Recruiting --> Active, not recruiting
  • ||||||||||  Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
    Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy, Stroma, Metastases:  Selinexor as Single Agent and With Imatinib in Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (SeliGIST) (clinicaltrials.gov) -  Mar 27, 2023   
    P1/2,  N=30, Active, not recruiting, 
    Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial completion date: Dec 2022 --> Apr 2023 | Trial primary completion date: Apr 2022 --> Apr 2023